Taysha Gene Therapies
Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.
$5.87
After-hours close+0.10 (+1.73%)
At close$5.77(−3.19%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.11 | −$0.13 | −14.8% |
| May 2026 | −$0.10 | −$0.12 | −20.0% |
| Mar 2026 | −$0.11 | −$0.08 | +27.3% |
| Nov 2025 | −$0.09 | −$0.09 | 0.0% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.14 | — | — | $755.6K | — | — |
| Aug 11, 2026 | −$0.11 | −$0.13 | −14.8% | $680.0K | $0 | −100.0% |
| May 6, 2026 | −$0.10 | −$0.12 | −20.0% | $755.6K | — | — |
| Mar 19, 2026 | −$0.11 | −$0.08 | +27.3% | $2.2M | $5.5M | +144.5% |
| Nov 4, 2025 | −$0.09 | −$0.09 | 0.0% | $1.9M | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 15, 2025 | ||||||
| Feb 26, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 19, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 28, 2023 | ||||||
| Nov 8, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 16, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 16, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 3, 2021 | ||||||
| Nov 12, 2020 | ||||||
| Sep 25, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Dec 31, 2019 | ||||||